Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors
February 12, 2019 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective March 19,...
Emergent BioSolutions Announces Daniel J. Abdun-Nabi to Retire as CEO; Robert G. Kramer, Sr. to Become President and CEO
January 04, 2019 07:00 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its CEO Daniel J. Abdun-Nabi will be retiring and that its board of directors has...
WABCO Signs $950 Million Long-Term Agreement with Global Manufacturer to Supply its Leading Braking, Advanced Driver Assistance Systems and Efficiency Technologies
December 20, 2018 06:30 ET
|
WABCO Holdings Inc.
BRUSSELS, Belgium, Dec. 20, 2018 (GLOBE NEWSWIRE) -- WABCO Holdings Inc. (NYSE: WBC) (www.wabco-auto.com), the leading global supplier of braking control systems and other advanced technologies that...
WABCO Signs Long-Term Agreement to Supply a Broad Portfolio of its Advanced Technologies to Support Hyundai Motor Company’s New Medium-Duty Truck Launch in South Korea
November 08, 2018 06:30 ET
|
WABCO Holdings Inc.
SHANGHAI, China, Nov. 08, 2018 (GLOBE NEWSWIRE) -- WABCO Holdings Inc. (NYSE: WBC) (www.wabco-auto.com), the leading global supplier of braking control systems and other advanced technologies that...
Emergent BioSolutions to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference
June 08, 2018 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., June 08, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will present a corporate overview and...
Emergent BioSolutions Reports First Quarter 2018 Financial Results
May 03, 2018 16:30 ET
|
Emergent BioSolutions
Reaffirms full year 2018 financial forecast and operational goalsProvides Q2 2018 revenue forecast of $205M-$230M GAITHERSBURG, Md., May 03, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions...
Emergent BioSolutions Awarded One-Year CDC Contract Valued at $26 Million for Vaccinia Immune Globulin Program
February 28, 2018 06:45 ET
|
Emergent Biosolutions, Inc.
GAITHERSBURG, Md., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a contract award by the Centers for Disease Control and Prevention (CDC) valued at $26...
Emergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 Guidance
November 02, 2017 16:15 ET
|
Emergent Biosolutions, Inc.
GAITHERSBURG, Md., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and nine months ended September 30, 2017. FINANCIAL HIGHLIGHTS ...
Emergent BioSolutions to Release Third Quarter and Nine Months 2017 Financial Results and Conduct a Conference Call on November 2, 2017
October 19, 2017 07:00 ET
|
Emergent Biosolutions, Inc.
GAITHERSBURG, Md., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) will release its financial results for the third quarter and nine months of 2017 immediately after market close...
Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance
August 03, 2017 16:15 ET
|
Emergent BioSolutions Inc.
GAITHERSBURG, Md., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and six months ended June 30, 2017. FINANCIAL HIGHLIGHTS (in...